Quimioterapia em tumores de cabeça e pescoço

Blunk, Vivian; Bueno, Luciana Moro; Nicoletti, André Gustavo Bombana; Gasparini, Flávia Faganello; Guedes, Keyla Facchin; Pico, Kelly Aparecida; Costa, Luciano Megale; Kanda, Jossi Ledo; Nivola, Ariovaldo C; Giglio, Auro Del; Zatta, Simone Meneghetti; Gertner, Sulamita Kramarski.
Arq. méd. ABC ; 20(1/2): 2-6, 1997. graf
Artigo em Português | LILACS | ID: lil-251146

Documentos relacionados

  1. Immune checkpoint blockade provokes resident memory T cells to eliminate head and neck cancer.
  2. Nanoparticle therapy for head and neck cancers.
  3. CD4<sup>+</sup> T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy.
  4. Drug-related problems in head and neck cancer patients identified by repeated medication reviews on consecutive therapy cycles.
  5. Novel Insights of Anti-EGFR Therapy in HNSCC: Combined with Immunotherapy or Not?
  6. Construction of CpG Delivery Nanoplatforms by Functionalized MoS<sub>2</sub> Nanosheets for Boosting Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.
  7. The potential roles of antibody-drug conjugates in head and neck squamous cell carcinoma.
  8. Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
  9. Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).
  10. Silmitasertib, a casein kinase 2 inhibitor, induces massive lipid droplet accumulation and nonapoptotic cell death in head and neck cancer cells.